Nakamura Hironori, Yokoyama Haruko, Takayanagi Risa, Yoshimoto Koichi, Nakajima Akihiro, Okuyama Kiyoshi, Iwase Osamu, Yamada Yasuhiko
Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):39-44. doi: 10.1007/s13318-014-0175-z. Epub 2014 Jan 28.
5-HT(3) receptor antagonists are widely used as antiemetic agents in clinical setting, of which palonosetron, with a long elimination half life (t(1/2)), has recently become available. It is important to evaluate the concentration of serotonin when investigating the antiemetic effects of 5-HT(3) receptor antagonists, as those effects are not based solely on the t(1/2) value. We theoretically evaluated the antiemetic effects of three 5-HT(3) receptor antagonists (granisetron, azasetron, palonosetron) on cisplatin-induced nausea and vomiting by estimating the time course of the 5-HT(3) receptor occupancy of serotonin. We estimated the 5-HT(3) receptor occupancy of serotonin in the small intestine, based on the time course of plasma concentration of each 5-HT(3) receptor antagonist and the time course of concentration of serotonin near the 5-HT(3) receptor in the small intestine after administration of cisplatin. The antiemetic effect of each 5-HT(3) receptor antagonist was evaluated based on the normal level of 5-HT(3) receptor occupancy of serotonin. Our results suggest that an adequate antiemetic effect will be provided when a dose of 75 mg/m(2) of cisplatin is given to patients along with any single administration of granisetron, azasetron, or palonosetron at a usual dose. On the other hand, the 5-HT(3) receptor occupancy of serotonin was found to be significantly lower than normal for several days after administration of palonosetron, as compared to granisetron and azasetron, indicating that constipation may be induced. Our results show that granisetron, azasetron, and palonosetron each have an adequate antiemetic effect after administration of 75 mg/m(2) of cisplatin.
5-羟色胺(5-HT)(3)受体拮抗剂在临床中广泛用作止吐药,其中半衰期(t(1/2))长的帕洛诺司琼最近已上市。在研究5-HT(3)受体拮抗剂的止吐作用时,评估血清素浓度很重要,因为这些作用并非仅基于t(1/2)值。我们通过估计血清素对5-HT(3)受体的占据时间过程,从理论上评估了三种5-HT(3)受体拮抗剂(格拉司琼、阿扎司琼、帕洛诺司琼)对顺铂引起的恶心和呕吐的止吐作用。我们根据每种5-HT(3)受体拮抗剂的血浆浓度时间过程以及顺铂给药后小肠中5-HT(3)受体附近血清素浓度的时间过程,估计了小肠中血清素对5-HT(3)受体的占据情况。基于血清素对5-HT(3)受体的正常占据水平,评估了每种5-HT(3)受体拮抗剂的止吐作用。我们的结果表明,当给患者静脉注射75mg/m(2)顺铂并同时单次给予常规剂量的格拉司琼、阿扎司琼或帕洛诺司琼时,将产生足够的止吐效果。另一方面,与格拉司琼和阿扎司琼相比,帕洛诺司琼给药后数天血清素对5-HT(3)受体的占据率显著低于正常水平,表明可能会引起便秘。我们的结果表明,格拉司琼、阿扎司琼和帕洛诺司琼在静脉注射75mg/m(2)顺铂后均具有足够的止吐效果。